medwireNews: Tirzepatide is more effective at reducing both glycated hemoglobin (HbA1c) and weight in patients with type 2 diabetes than semaglutide, suggest the results of a network meta-analysis reported at the 59th EASD Annual Meeting.
09-10-2023 | Type 2 Diabetes | Editor's Choice | News